XML 51 R27.htm IDEA: XBRL DOCUMENT v3.20.4
Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details) - Customer Concentration Risk
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Sales revenue, net | Incyte Corporation (Incyte)      
Concentration Risk [Line Items]      
Percentage of significant accounts receivable 47.00% 35.00% 68.00%
Sales revenue, net | Janssen Biotech Inc.      
Concentration Risk [Line Items]      
Percentage of significant accounts receivable 19.00%    
Sales revenue, net | Zai Lab Limited (Zai Lab)      
Concentration Risk [Line Items]      
Percentage of significant accounts receivable 11.00% 29.00%  
Sales revenue, net | Les Laboratoires Servier and Institut de Recherches Servier (Servier)      
Concentration Risk [Line Items]      
Percentage of significant accounts receivable   18.00%  
Accounts receivable | Incyte Corporation (Incyte)      
Concentration Risk [Line Items]      
Percentage of significant accounts receivable   62.00%  
Accounts receivable | Janssen Biotech Inc.      
Concentration Risk [Line Items]      
Percentage of significant accounts receivable 87.00%    
Accounts receivable | Zai Lab Limited (Zai Lab)      
Concentration Risk [Line Items]      
Percentage of significant accounts receivable   23.00%